Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study
- PMID: 23845016
- DOI: 10.1111/jsm.12236
Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study
Abstract
Introduction: Men with comorbid erectile dysfunction (ED) and premature ejaculation (PE) may be concomitantly prescribed a phosphodiesterase type 5 (PDE5) inhibitor and dapoxetine.
Aim: Evaluate efficacy and safety of dapoxetine 30 mg and 60 mg on demand (prn) in men with PE and ED who were being treated with PDE5 inhibitors.
Methods: This randomized, double-blind, placebo-controlled, flexible-dose, multicenter study enrolled men ≥18 years who met diagnostic criteria for PE including intravaginal ejaculatory latency time (IELT) of ≤2 minutes in ≥75% of sexual intercourse episodes; were on stable regimen of a PDE5 inhibitor; and had International Index of Erectile Function-erectile function domain score ≥21. Subjects received placebo, dapoxetine 30 mg, or dapoxetine 60 mg prn (1-3 hours before intercourse) for 12 weeks.
Main outcome measure: Stopwatch-measured average IELT, Clinical Global Impression of Change (CGIC) in PE, Premature Ejaculation Profile (PEP), and treatment-emergent adverse events (TEAEs).
Results: Of 495 subjects randomized, 429 completed the study. Arithmetic mean average IELT significantly increased with dapoxetine vs. placebo at end point (5.2 vs. 3.4 minutes) and weeks 4, 8, and 12 (P ≤ 0.002 for all). Men who described their PE at least "better" using the CGIC were significantly greater with dapoxetine vs. placebo at end point (56.5% vs. 35.4%) and weeks 4, 8, and 12 (P ≤ 0.001 for all). Significantly better outcomes were also reported with dapoxetine vs. placebo on PEP measures. Incidence of TEAEs was 20.0% and 29.6% in placebo- and dapoxetine-treated subjects, respectively (P = 0.0135). TEAEs led to discontinuation in 1.6% of subjects in both groups. Most frequent TEAEs were known adverse drug reactions of dapoxetine treatment including nausea (9.2%), headache (4.4%), diarrhea (3.6%), dizziness (2.4%), and dizziness postural (2.4%).
Conclusions: In men with PE and comorbid ED on a stable regimen of PDE5 inhibitor, dapoxetine provided meaningful treatment benefit and was generally well tolerated.
Trial registration: ClinicalTrials.gov NCT01063855.
Keywords: Concomitant Treatment; Dapoxetine; Erectile Dysfunction; Phosphodiesterase Type 5 Inhibitor; Premature Ejaculation.
© 2013 Janssen Pharmaceutical Research & Development, LLC. Journal of Sexual Medicine © 2013 International Society for Sexual Medicine.
Comment in
-
Re: Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.J Urol. 2014 Apr;191(4):1077-8. doi: 10.1016/j.juro.2014.01.070. Epub 2014 Jan 17. J Urol. 2014. PMID: 24703142 No abstract available.
Similar articles
-
Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine.J Sex Med. 2010 Jan;7(1 Pt 1):256-68. doi: 10.1111/j.1743-6109.2009.01560.x. Epub 2009 Oct 29. J Sex Med. 2010. PMID: 19878447 Clinical Trial.
-
Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study.J Sex Med. 2013 Nov;10(11):2832-41. doi: 10.1111/jsm.12287. Epub 2013 Aug 12. J Sex Med. 2013. PMID: 23937271 Clinical Trial.
-
Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.J Sex Med. 2011 Feb;8(2):524-39. doi: 10.1111/j.1743-6109.2010.02097.x. Epub 2010 Nov 8. J Sex Med. 2011. PMID: 21059176
-
Dapoxetine: in premature ejaculation.Drugs. 2010 Jul 30;70(11):1433-43. doi: 10.2165/11204750-000000000-00000. Drugs. 2010. PMID: 20614950 Review.
-
Dapoxetine for premature ejaculation.Expert Opin Pharmacother. 2010 Jul;11(10):1741-52. doi: 10.1517/14656566.2010.493174. Expert Opin Pharmacother. 2010. PMID: 20540653 Review.
Cited by
-
Current and emerging treatment options for premature ejaculation.Nat Rev Urol. 2022 Nov;19(11):659-680. doi: 10.1038/s41585-022-00639-5. Epub 2022 Aug 25. Nat Rev Urol. 2022. PMID: 36008555 Review.
-
Do pornography use and masturbation play a role in erectile dysfunction and relationship satisfaction in men?Int J Impot Res. 2023 Sep;35(6):548-557. doi: 10.1038/s41443-022-00596-y. Epub 2022 Jul 15. Int J Impot Res. 2023. PMID: 35840678
-
Selective Serotonin Re-Uptake Inhibitors for Premature Ejaculation in Adult Men: A Cochrane Systematic Review.World J Mens Health. 2022 Apr;40(2):257-263. doi: 10.5534/wjmh.210155. Epub 2022 Jan 2. World J Mens Health. 2022. PMID: 35021307 Free PMC article.
-
An update on the treatment of premature ejaculation: A systematic review.Arab J Urol. 2021 Aug 4;19(3):281-302. doi: 10.1080/2090598X.2021.1943273. eCollection 2021. Arab J Urol. 2021. PMID: 34552780 Free PMC article. Review.
-
Ejaculatory dysfunction in men with diabetes mellitus.World J Diabetes. 2021 Jul 15;12(7):954-974. doi: 10.4239/wjd.v12.i7.954. World J Diabetes. 2021. PMID: 34326948 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous